Insulin lispro
Insulin lispro
Definition
A recombinant therapeutic agent which is chemically identical to or similar to endogenous human insulin. In lispro insulin, the amino acid proline at B-28 and the amino acid lysine at B-29 are reversed, resulting in the rapid dissolution of this insulin to a monomer that is absorbed rapidly after subcutaneous administration. Lispro insulin is equipotent to human insulin on a molar basis but its effects are faster and of shorter duration. Endogenous insulin, a pancreatic hormone composed of two polypeptide chains, is important in the normal metabolism of carbohydrates, proteins and fats, promoting glucose utilization and protein synthesis; it has anabolic effects on many types of tissues. (NCI04)
Also known as Humalog, INSULIN LISPRO — per NCIT
Also identified as
- ATC A10AB per NCIT
- ATC A10AC per NCIT
- ATC A10AD per NCIT
- NCIT NCIT:C29123 per NCIT
Indications
| Disease | Relation | Source |
|---|---|---|
| Diabetes mellitus type 2 | may treat | MEDRT · Public domain (U.S. Government work) |
| Hyperglycemia | may treat | MEDRT · Public domain (U.S. Government work) |
| Type 1 diabetes mellitus | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Alimentary part of gastrointestinal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Pancreas | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.